Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Invitation to Nanoform’s Q2 2024 Report Presentation

Press release Nanoform Finland Plc August 16, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q2 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q2 2024 report August 29[th], 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO

Cyxone AB publishes outcome of rights issue

The subscription period in Cyxone AB’s ("Cyxone" or the "Company") rights issue ended on 15 August 2024 (the "Rights Issue"). The Rights Issue was subscribed to a total of approximately 27.3 percent, including pre-subscription commitments. Cyxone will thus be provided proceeds of approximately SEK 6.3 million before deduction of transaction related costs.Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 6.3 million including pre-subscription commitments of approximately SEK 0.26 million, which corresponds to a subscription rate of approximately 27.

Implementing Lessons Learned: Broadening Our Scope

The purpose of this short article is to clarify the value we provide and to announce a broader vision and scope for Katalysen Ventures going forward.In recent years, the term "financial stress" has become all too familiar to many of us. Whether it is struggling businesses, declining portfolio values, managing distressed assets, or the effects of inflation and rising interest rates, the financial landscape has presented significant challenges. This has led us to draw even more on our core strengths: working with diverse stakeholders and coordinating diverse resources in ventures - a term

TF Bank: Monthly statistics July 2024

The total loan portfolio amounted to SEK 20,067 million at the end of July. Compared to July 2023, the loan portfolio has increased by 18 % in local currencies.  Month Jul-24 Jul-23 ChangeCredit Cards   New lending, SEK million 1,602 923 74 %Ecommerce Solutions   Transaction volume*, SEK million 929 957 -3 %Consumer Lending   New lending, SEK million 446 462 -3 %  Cumulative for the year Jan-Jul 24 Jan-Jul 23 ChangeCredit Cards   New lending, SEK million 8,764

Himalaya Shipping Ltd. (HSHP) Announces its Preliminary Results for the Three and Six Months Ended June 30, 2024

Hamilton, Bermuda, August 16, 2024 Himalaya Shipping Ltd. (“Himalaya,” “Himalaya Shipping” or the “Company”) announces preliminary unaudited results for the three and six months ended June 30, 2024. Highlights for the Second Quarter of 2024 -  Successful delivery and commencement of operations of the remaining three 210,000 dwt Newcastlemax dual fuel newbuildings in the second quarter of 2024, ordered from New Times Shipyard, resulting in a total delivered fleet of 12 vessels. -  Total operating revenues of $31.2 million, which is an average time charter equivalent (“TCE”)

CS MEDICA Q3 2023/2024 Results: Strong Revenue Growth of 400% Despite Production Delays

Revenue Grew Over 400% Year-to-Date, and Order Intake Hit mDKK 49.3, Fueled by Strategic Partnerships and ExpansionCS MEDICA, a Danish MedTech leader specializing in pain management, autoimmune diseases, and stress-related disorders, reports its financial performance for the third quarter of 2023/2024 (April–June 2024). In a display of resilience and strategic insight, CS MEDICA met its Q3 revenue target despite facing production delays that necessitated carrying over mDKK 1.5 million to the next quarter. The company delivered mDKK 0.5 in net sales this quarter, achieving a robust year-to-

Valmet and Spinnova Plc sign a partnership agreement regarding process equipment for textile fibre production

Valmet Oyj press release, August 16, 2024, at 9:30 a.m. EESTValmet and Spinnova Plc have signed a strategic partnership agreement where Valmet is appointed as the exclusive partner to supply process equipment for textile fibre production to Spinnova’s technology customers. The exclusivity agreement is valid for four years, with termination options based on project progress. The agreement includes an exclusivity fee, which is based on realized project deliveries. Valmet has previously supplied drying technology to Woodspin, a joint venture between Spinnova and Suzano, for its factory

Interim report January – June 2024

GARO Electrification reports a stable quarter while GARO E-mobility continues to face challenging market conditions APRIL – JUNE 2024 · Net sales amounted to MSEK 306.3 (386.0). · Net sales declined 21% (+10). · EBIT amounted to MSEK -4.3 (18.2). · EBIT margin amounted to -1.4% (4.7). · Net income was MSEK -8.9 (20.1). · Loss per share amounted to SEK -0.18 (earnings: 0.40). JANUARY – JUNE 2024 · Net sales amounted to MSEK 598.8 (756.3). · Net sales declined 21% (+3). · EBIT amounted to MSEK -10.9 (45.9). · EBIT margin amounted to -1.8% (6.1). ·

The subscription period in Dicot Pharma's rights issue begins today

Uppsala, Sweden, August 16, 2024. The subscription period in Dicot Pharma AB's rights issue of units consisting of shares and warrants of series 6 begins today, in which the public also has the opportunity to apply interest in subscribing units. The rights issue was resolved by the Board of Directors on August 7, 2024 (the "Rights Issue").NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION

GARO starts recruitment of a new CEO. Patrik Andersson will remain CEO until his replacement takes up the position

The recruitment of a new CEO has started and the aim is to announce the appointment of a successor during the autumn, with an expected start in the first quarter of 2025. Under Patrik Andersson’s leadership, GARO has completed several strategic initiatives, such as organizing operations into two business areas (GARO Electrification and GARO E-mobility), developing the new product platform GARO Entity, and investing in production and delivery capacity. Going forward, GARO will be entering an increasingly international and growth-oriented phase in order to capitalize on investments made.

PHI enters the US capital market – shares now also traded on OTCQB

Phase Holographic Imaging (PHI) is thrilled to announce its official approval for listing on the OTCQB Venture Market in the U.S., with trading commencing yesterday, Thursday, August 15th. This marks an important milestone in expanding our reach and enhancing accessibility for U.S. investors, setting the stage for improved engagement and continued growth.Effective August 15th, PHI has been admitted to trading on the OTCQB under the symbol "PHIXF". OTC Markets Group operates regulated markets for trading U.S. and international securities, offering global companies the opportunity to make

Submission of Parys Mountain Mine Environmental Impact Assessment Scoping Report

    Trading Symbol AIM: AYM   16 August 2024   Anglesey Mining plc (“Anglesey” or “the Company”)   Submission of Parys Mountain Mine Environmental Impact Assessment Scoping Report   Anglesey Mining plc (AIM:AYM), is pleased to announce that it has reached an important project milestone with the formal submission on 31st July 2024 of the Parys Mountain Mine Environmental Impact Assessment (EIA) Scoping Report to the North Wales Minerals and Waste Planning Service (the “Planning Service”) as part of a formal EIA Scoping Opinion request. The

Imfinzi approved in US for resectable lung cancer

16 August 2024  Imfinzi approved in the US for the treatment of resectablenon-small cell lung cancer before and after surgeryBased on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk ofrecurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy has been approved in the US for the treatment of adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma

Heimstaden Bostad AB Q2 2024 Results

Highlights (figures in brackets refer to same quarter last year):  ·The Privatisation Plan continued to deliver in line with ramp-up expectations as H1 total sales reached SEK 2,818 million. In the second quarter of 2024, 363 units were sold with a 29.0% premium to book value  ·The NOI margin improved to 71.5% (69.0%) and the LTM NOI margin was 68.4% (66.0%)  ·NOI growth offset slightly expanding yields, leading to a 0.4% (-2.1%) increase in property values  ·Rental income at SEK 3,938 million (3,707) and like-for-like rental growth of 5.1% (5.6%)  ·Real

Heimstaden AB Q2 2024 Results

Highlights (figures in brackets refer to same quarter last year):  ·The Privatisation Plan continued to deliver in line with ramp-up expectations as H1 total sales reached SEK 2,818 million. In the second quarter of 2024, 363 units were sold with a 29.0% premium to book value  ·The NOI margin improved to 71.4% (69.0%) and the LTM NOI margin was 68.3% (66.2%)  ·NOI growth offset slightly expanding yields, leading to a 0.4% (-2.1%) increase in property values  ·Rental income at SEK 3,943 million (3,800) and like-for-like rental growth of 5.1% (5.7%)  ·Real

Viking Line: Half year financial report January - June 2024

Viking Line Abp                           HALF YEAR FINANCIAL REPORT                 15.08.2024, 9.00 AMA half-year characterized by weaker demand   JANUARY-JUNE 2024 (compared to January–June 2023) · Sales amounted to EUR 219.1 M (EUR 226.3 M). · Other operating revenue was EUR 0.6 M (EUR 8.9 M, including the EUR 8.6 M capital gain from the sale of Rosella.)  · Operating income totalled EUR -4.3 M (EUR 17.1 M, including the EUR 8.6 M capital gain from the sale of Rosella.)  · Net financial items were EUR -8.1 M (EUR -7.7 M).  · Income before taxes totalled EUR -

Ranplan Group AB – Interim Report Jan - Jun 2024

2024-08-16 08:00 CET The period in summary First half of 2024 (first half of 2023) · Total income amounted to SEK 14.0 million (11.2 million)[1] · Net sales amounted to SEK 6.6 million (6.2 million) · Total revenues amounted to SEK 11.4 million (8.1 million) · Operating income amounted to SEK -5.5 million (-14.5 million) · Net income amounted to SEK -6.6 million (-15.8 million) · Earnings per share amounted to SEK -0.14 (-0.51) · Cash flow from operations amounted to -SEK 3.6 million (-10.7 million) · Cash at the end of the period amounted to SEK 2.4 million (

Interim report January – June 2024

Increased net sales after acquisition and strong cash flowApril – JUNe 2024 •    Net sales amounted to SEK 395.9 million (274.6), an increase of 44%. •    Net sales for comparable segments decreased by SEK 10.4 million, adecrease by 4%.•    Operating profit amounted to SEK 25.8 million (32.0), a decrease by 19%. •    The operating margin decreased to 6.5% (11.6).•    Non-recuring costs are included in the operating profit with SEK -9.0million. In the comparing quarter electricity grant of SEK 5.5 million wasreceived.•    The profit for the period amounted to SEK 16.5

Cereno Scientific expands patent protection for PAH drug candidate CS1’s third patent family in Brazil

Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a new granted patent in CS1’s third patent family has been issued in Brazil.“I am happy to announce another granted patent for our leading drug candidate, CS1, in Phase II development for the rare disease Pulmonary Arterial Hypertension (PAH). We are continuously working to expand the patent protection for our assets. The newly granted patent is Cereno’s first in Brazil, a major pharmaceutical market, and will play an

Kamux Corporation’s Half Year Financial Report for January 1—June 30, 2024: Revenue decreased and adjusted operating profit decreased significantly, a weak Q2 in Sweden

Kamux Corporation, Half Year Financial Report, 16.8.2024 at 9:00 Kamux Corporation’s Half Year Financial Report for January 1—June 30, 2024: Revenue decreased and adjusted operating profit decreased significantly, a weak Q2 in Sweden This is a summary of Kamux Corporation’s Half Year Financial Report for January 1—June 30, 2024. The complete report is attached to this release and is also available at the company website at www.kamux.com. The figures in parentheses refer to the comparison period, i.e., the same period in the previous year, unless stated otherwise. April–June in

Polymer Factory Sweden AB (publ) Interim Report Q2 2024

The period in summary Second quarter, April-June 2024 · Products from the SpheriCal® platform were featured in a scientific article, co-authored by Polymer Factory · The Company exhibited and presented at the ASMS conference in Anaheim, USA in June · The Company launched SpheriCal® for IM-MS · Trading of the Company's share moved from Spotlight Stock Market to Nordic SME on Nordic Growth Market Year to date, January-June 2024 · The Company entered into a distribution agreement regarding SpheriCal® · Result for the period increased compared to same period last

Delårsrapport Q2 2024

1 JANUARI – 30 JUNI 2024FLOWSCAPE TECHNOLOGY AB (publ),ORG.Nr. 556725-4866Styrelsen och verkställande direktören för Flowscape Technology AB avger härmed rapport för perioden januari – juni 2024. Belopp anges i tusentals kronor. Siffror inom parentes avser motsvarande period föregående år This information is only available in SwedishJanuari – juni i korthet, concern Andra kvartalet (April-juni) · Nettomsättningen uppgick till 10 391 (11 668) TSEK · Rörelseresultatet före avskrivningar uppgick till -212 (1 307) TSEK · Resultat efter finansiella poster uppgick till -2

There are no items matching the current filter
There are no more items matching the current filter
Back to top